Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer
Chuling Hu,Yan Liu,Wei Cao,Na Li,Shen Gao,Zhuo Wang,Fenfen Gu
DOI: https://doi.org/10.2147/ijn.s440332
IF: 7.033
2024-01-18
International Journal of Nanomedicine
Abstract:Chuling Hu, 1, &ast Yan Liu, 2, &ast Wei Cao, 3, &ast Na Li, 4 Shen Gao, 5 Zhuo Wang, 5 Fenfen Gu 2 1 Department of Pharmacy, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children's Hospital of Jiaxing University, Jiaxing, People's Republic of China; 2 Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China; 3 Department of Neurovascular Disease, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China; 4 Department of Pathology, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children's Hospital of Jiaxing University, Jiaxing, People's Republic of China; 5 Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhuo Wang; Fenfen Gu, Email ; Introduction: Chemotherapy is still the treatment of choice for advanced triple-negative breast cancer. Chemotherapy combined with immunotherapy is being tried in patients with triple-negative breast cancer. As a kind of "cold tumor", triple-negative breast cancer has a bottleneck in immunotherapy. Indoleamine 2, 3-dioxygenase-1 inhibitors can reverse the immunosuppressive state and enhance the immune response. Methods: In this study, mesoporous silica nanoparticles were coated with the chemotherapeutic drug doxorubicin and indoleamine 2, 3-dioxygenase 1 inhibitor 1-Methyl-DL-tryptophan (1-MT), and then encapsulate the surfaces of a triple-negative breast cancer cell membrane to construct the tumor dual-targeted delivery system CDIMSN for chemotherapy and immunotherapy, and to investigate the immunogenic death effect of CDIMSN. Results and discussion: The CDIMSN could target the tumor microenvironment. Doxorubicin induced tumor immunogenic death, while 1-MT reversed immunosuppression. In vivo findings showed that the tumor size in the CDIMSN group was 2.66-fold and 1.56-fold smaller than that in DOX and DIMSN groups, respectively. CDIMSN group was better than naked DIMSN in stimulating CD8 + T cells, CD4 + T cells and promoting Dendritic Cells(DC) maturation. In addition, blood analysis, biochemical analysis and Hematoxylin staining analysis of mice showed that the bionic nanoparticles had good biological safety. Keywords: immunogenic cell death, doxorubicin, bionic nanoparticle, IDO1 inhibitor, triple-negative breast cancer Graphical Triple-negative breast cancer (TNBC) is a subtype of breast cancer. It is heterogeneous and does not express estrogen receptor, progesterone receptor, or human epidermal growth factor-2. 1 The incidence of TNBC is approximately 10–15% of breast cancer in Western countries and 23.8% in China. 2,3 TNBC is characterized by a poor prognosis and high recurrence, metastasis, and mortality rates. 4–6 Cytotoxic drugs taxane and anthracycline are the main treatment for triple-negative breast cancer, but patients have became resistant to chemotherapy drugs. 7–9 With the development of tumor immunotherapy, a large number of immunotherapies have been approved for clinical application. Immune checkpoint inhibitors targeting PD-1 and its ligands PD-L1 and CTLA-4 have shown promising efficacy in a wide range of solid and hematological tumors. 10–13 Although tumor immunotherapy such as checkpoint inhibitors has achieved considerable therapeutic effect, it faces great challenges due to insufficient immunogenicity and immunosuppression of tumor microenvironment. 14,15 In this process, tumor-associated macrophages (TAMs) play an important role in coordinating tumor immunity. TAM is a major immunosuppressive cell component in the tumor microenvironment and is involved in the production of tumor factors, recruitment of Tregs, and dysfunction of tumor killer effector cells (such as CD8 + T and NK cells). Studies have shown that targeting tumor-associated macrophages to polarize tumor-promoting M2-type TAM into anti-tumor M1-type TAM can effectively inhibit tumor growth. 16–18 Therefore, knowing how to enhance tumor immunogenicity and remove the immunosuppression of tumor microenvironment to increase the recognition and presentation of tumor antigens are very important to activating the antitumor immune response and improving the effect of antitumor immunotherapy. Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting enzyme that catalyzes catabolism of L-tryptophan through the kynurenine pa -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology